 Drug developer C4X Discovery Holdings PLC AIM:C4XD has hit the first milestone in a licensing deal with Sanofi after progressing pre-clinical trials for an immunotherapy drug. The company is developing an oral interleukin 17A inhibitor that could be used to treat autoimmune diseases. 